Clinical trial · Interventional
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Other new drugs
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs in different combinations may kill more cancer cells. It is not yet know which treatment regimen is more effective in treating Hodgkin lymphoma. PURPOSE: This phase III trial is studying three different therapy regimens to compare how well they work in treating patients with previously untreated Hodgkin lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (19)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ABVD regimen | Drug | — | UNRESOLVED |
| allogeneic hematopoietic stem cell transplantation | Procedure | — | UNRESOLVED |
| autologous hematopoietic stem cell transplantation | Procedure | — | UNRESOLVED |
| bleomycin sulfate | Biological | Bleomycin | ALIAS |
| carmustine | Drug | Carmustine | ALIAS |
| cisplatin | Drug | Cisplatin | ALIAS |
| cytarabine | Drug | Cytarabine | ALIAS |
| dacarbazine | Drug | Dacarbazine | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group 1 (favorable prognosis)
- description
- Patients receive ABVD and VABEM chemotherapy.
- interventionNames
- Biological: bleomycin sulfate
- Drug: ABVD regimen
- Drug: carmustine
- Drug: dacarbazine
- Drug: doxorubicin hydrochloride
- Drug: etoposide
- Drug: methylprednisolone
- Drug: vincristine sulfate
- Drug: vindesine
- type
- EXPERIMENTAL
- label
- Group 2 (intermediate prognosis)
- description
- Patients receive ABVD and VABEM chemotherapy.
- interventionNames
- Biological: bleomycin sulfate
- Drug: ABVD regimen
- Drug: carmustine
- Drug: dacarbazine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
INCLUSION CRITERIA * Life expectancy \> 3 months * LVEF normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Must be able to undergo follow-up for ≥ 15 years * No impaired cardiac function that would preclude the administration of an anthracycline * No other prior or concurrent malignancy, except for carcinoma in situ of the cervix or basal cell skin cancer * No respiratory, kidney, or liver failure or other severe clinical insufficiency that would preclude study treatment * No HIV or hepatitis B virus positivity * No other disease that would preclude treatment with chemotherapy or radiotherapy EXCLUSION CRITERIA: * No concurrent participation in another experimental trial
References
Publications (0)
Data not yet available